Ozempic (semaglutide) is a GLP-1 receptor agonist licensed for type 2 diabetes treatment in the UK, administered subcutaneously once weekly
Microdosing GLP-1s means starting at significantly lower doses than standard guidelinessometimes as low as 0.05 to 0.1 mg of semaglutide per week, compared to the usual starting dose of 0.25 mg
GLP-1 receptor agonists are a class of medications that mimic the gut hormone glucagon-like peptide-1
Stick with veterinary-grade or properly compounded sources
Therefore, the combined use of GLP-1 RAs with therapies targeting intrahepatic pathways, such as thyroid hormone receptor (THR-) agonists, fibroblast growth factor-21 (FGF21) analogues, and peroxisome proliferator-activated receptor (PPAR) agonists, presents a promising approach for MASH treatment
The research, published in the journal Frontiers in Psychiatry , used health data from more than 142,000 patients from the All of Us Research Program and adds to a growing body of evidence indicating that GLP-1 medications may have an influence on dopamine signaling and other neural pathways that drive cravings not just for food but other substances
